PARIS, May 26, 2010 /PRNewswire/ -- InspireMD, Ltd. announced today the next generation MGuard stent, MGuard Prime(R), a net protective Cobalt Chromium stent system. MGuard Prime(R) offers an advanced patented Cobalt Chromium design, superior flexibility and excellent deliverability on top of the established benefits of the MGuard MicroNet(R) technology.
MGuard(TM) is now available with an improved delivery system. Recently InspireMD introduced MGuard with a new improved delivery system in selected regions. The new delivery system offers a state of the art design and a superior deliverability. "We are very pleased with the flexibility and performance of the new delivery system. In our testing we have experienced a 15% improvement in crossing profile and 45% improvement in pushability resistance. These improvements will directly benefit Acute MI patients throughout the world," said Eli Bar, CTO and VP R&D of InspireMD.
InspireMD will hold an Evening Symposium at the PCR this evening at 6:30-8:00pm at the Concorde Lafayette Hotel in Paris. The symposium "MGuard - 2 Years Experience in Acute MI" will be chaired by Dr. Martin B. Leon.
MGuard final adjudicated results of the MAGICAL trial, including the long awaited 6 months clinical FU results, will be presented for the first time at the EuroPCR. The MAGICAL Trial is a 60 patients STEMI study. Acute results as well as interim 30 day clinical results have previously been presented by Dr. Dariusz Dukek, the study's primary investigator.
Also coming up at the EuroPCR, presented for the first time, the final adjudicated results